Description: Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company's lead clinical-stage programs include TG4010, a therapeutic vaccine for the treatment of non-small cell lung cancer; Pexa-Vec, an oncolytic virus for the treatment of liver cancer; and TG4001, a therapeutic vaccine for cancers caused by the human papilloma virus. Its products in the clinical development stage also comprise TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and TG6002, an oncolytic virus for the treatment of various solid tumors, such as glioblastoma, as well as for the cancers of the stomach, colon, pancreas, and bladder. Transgene SA has collaboration agreements with Bristol-Myers Squibb, Merck KGaA, Pfizer, and University of California Davis; licensing agreements with SillaJen, Inc. and Ascend BioPharmaceutical; agreements with, Sanofi, BioInvent, Randox, and Emergent BioSolutions Inc.; and collaboration and licensing agreement with Valneva; and a strategic collaboration with NEC Corporation. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Home Page: www.transgene.fr
400, boulevard Gonthier d’Andernach
Illkirch-Graffenstaden,
67405
France
Phone:
33 3 88 27 91 00
Officers
| Name | Title |
|---|---|
| Dr. Alessandro Riva M.D. | CEO & Chairman of the Board |
| Ms. Lucie Larguier | Chief Financial Officer |
| Dr. Maurizio Ceppi | Vice President & Chief Scientific Officer |
| Mr. John Felitti J.D., LLM | VP, General Counsel & Corporate Secretary |
| Ms. Christelle Schwoerer | Chief Human Resources Officer |
| Mr. James Wentworth M.B.A., Ph.D. | VP & Chief Business Officer |
| Ms. Emmanuelle Dochy M.D. | VP of Medical Affairs & Chief Medical Officer |
| Ms. Gaelle Stadtler | VP & Director of Human Resources |
| Kaidre Bendjama | Project Leader of Personalized Cancer Vaccines |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 12.1993 |
| Price-to-Sales TTM: | 32.3911 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 146 |